Research Analysts Set Expectations for UTHR FY2025 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of United Therapeutics in a research report issued to clients and investors on Thursday, October 30th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings of $27.64 per share for the year, down from their previous forecast of $28.70. Cantor Fitzgerald has a “Overweight” rating and a $525.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Cantor Fitzgerald also issued estimates for United Therapeutics’ FY2026 earnings at $28.42 EPS.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.39 EPS.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a report on Wednesday, October 8th. Morgan Stanley set a $447.00 price target on United Therapeutics in a report on Wednesday, October 29th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Wednesday, October 29th. HC Wainwright boosted their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $501.90.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $437.33 on Monday. The stock has a market capitalization of $18.83 billion, a PE ratio of 16.57, a P/E/G ratio of 4.96 and a beta of 0.66. The business has a fifty day moving average price of $415.30 and a two-hundred day moving average price of $340.89. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $479.50.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 394,935 shares of company stock valued at $164,274,337. 10.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new position in United Therapeutics in the 2nd quarter worth about $29,000. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. SVB Wealth LLC acquired a new position in United Therapeutics in the 1st quarter worth about $32,000. Finally, Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.